Currently Viewing:
How Has the OCM Evolved? Year 1 Provider Updates
October 24, 2017
Will 2-Sided Risk Be a Reality in OCM?
October 24, 2017
Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM
October 24, 2017
Dr Jeff Patton Highlights Challenges Encountered With Implementing OCM
October 24, 2017
Physicians Need Clearer Metrics Before Taking on 2-Sided Risk
October 25, 2017
Terrill Jordan: Education and Data Are Key for OCM Success
October 25, 2017
The Commercial Payer OCM Experience: Year 1
October 25, 2017
Stakeholders Weigh-in on Payment Reform in Cancer Care
October 25, 2017
Dr Ira Klein Outlines the Biggest Challenge of Value-Based Drug Pricing
November 05, 2017
Dr Ira Klein on Pharmaceutical Interest in Alternative Payment Models
December 07, 2017
Dr Lucio Gordan: Improving Population Health Through Alternative Payment Models
December 08, 2017
Terrill Jordan: Year 1 Feedback on OCM
December 22, 2017
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26, 2017
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 03, 2018
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 04, 2018
Bo Gamble on COA's Role in 2018
January 05, 2018
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 07, 2018
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 09, 2018
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10, 2018
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11, 2018
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12, 2018
David Merrill and John Robinson Discuss Barriers to APMs, Factors of Interest
January 15, 2018
Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care
January 18, 2018
Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM
January 19, 2018
Currently Reading
Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges
January 20, 2018

Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges

Aetna is focusing on the healthcare triangle (patients, providers, and payers) and connecting those lines, said Roger Brito, DO, national director for oncology, Aetna.

Transcript (slightly modified)

How can payers and practices work together to implement OCM or other alternative payment models?

Our oncology medical home model at Aetna was established in 2014, the third quarter of 2014, and I like to tell our providers that we’re 2 years ahead of the OCM model as far as data and collaborating with our providers. At that point in time is when we enrolled our first OMH practices; we now have 21 practices throughout the United States. They parallel greatly, the oncology care model. We measure quality metrics, we participate in collaboration and communication, sometimes on a daily basis. There’s transparency and data sharing. It’s really an exciting time to be in the payer/provider mix. What we’re focusing on is what I call the healthcare triangle (patients, providers, and payers) and connecting those lines, because we’re both working for the same type of outcome, which is better health, delivery and care of our patients.

What are some challenges with implementing alternative payment models?

The challenges are that there are so many variables. So, do we look at pharmaceutical costs? Do we look at the total cost of the patient from their journey of diagnosing, pre-diagnosing, all the way through their journey, which takes them either to survivorship or end-of-life care? I think that’s where the difficulty lies. How do we assess, or put value on a member or patient’s journey and always keeping quality on the forefront? But, obviously if we can improve quality and maintain costs, or save costs without decreasing quality, that’s the goal, and that’s what we would like. I think the difficulty and the challenges, which segments do we take? Personally, I would love a global total cost care analysis that we could look at, and that would incorporate staging, survivorship, oncology care management, nurse navigator engagement, continuing on the relationship with the cancer survivor, and we know that cancer survivors can sometimes develop different diseases. So, if we’re engaged with our members up-front, we can then provide care for those special conditions they may have developed from having had cancer treatment as we move forward. I think the global model would be ideal; it might be the most difficult, but that would be my preference

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up